Briefly, COX-2 expression was negative to weak in 21% (COX-2 low) and moderate to strong in 79% (COX-2 high) of the carcinomas (Buskens et al, 2002; Tuynman et al, 2005). This evidence concerns the gene PTGS2 and carcinoma.